More consolidation:
ARCA biopharma And Oruka Therapeutics Announce Merger Agreement, The Deal Is Expected To Close in Q3 Of 2024
Benzinga 2024-04-03T07:32:00-04:00
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases
Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025
Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027
